

Tokyo (JST)

Oct. 29 Friday

Oct. 30 Saturday

Oct. 31 Sunday

8 0

**Epidemiology Around the World**  
**Chair1** Yoshikazu Nakamura  
**Chair2** Ermias Belay  
**Discussants :** Fu ChunMin

- van Stijn - Bringas Dimitriades, Diana:** 13-years of experience on Kawasaki disease in a single centre in the Netherlands
- Brian W. McCrindle:** Update on the Epidemiology of Kawasaki Disease in Canada
- Andre Rudolph:** Increase in Kawasaki disease incidence observed in 30-year in Scandinavia
- Ae Ryusuke:** Epidemiology of Kawasaki disease in Japan, 2019–2020: the 26th nationwide survey
- ChunMin Fu:** Epidemiology of Kawasaki Disease in Taiwan

9 0

- Rajni Kumrah :** Kawasaki disease incidence at Chandigarh, North India: 2015-2019
- Ryan Lucas:** Active Surveillance of Kawasaki Disease Diagnosis, Treatment, and Short-Term Outcomes in Australia (8minutes)

10

**"Tribute Session to Professor Tomisaku Kawasaki" (supported by Japan Heart Foundation)**  
**Chair1** Yoshio Imada  
**Chair2** Masato Takahashi  
**No Discussant**

10 0

**VIDEO**

- Tsubura Kawasaki
- J. Newburger
- Hiroshi Yanagawa
- Atsuko Suzuki
- Marian Melish
- HungChi Lue and MeiHwan Wu
- J Burns
- Surjit Singh
- Taco Kuijpers
- Eeva Salo

11 0

**The 1st Tomisaku Kawasaki Memorial Lecture**  
**Chair: Mamoru Ayusawa**  
**Speaker: Hirohisa Kato** ""Insight into cardiovascular issues of Kawasaki disease: My milestones for 50 years" "

12 0

**Legend Lecture (Supported by AHA) (All speakers are designated)**  
**Chair 1 Anitha John:** Medical Director, Washington Adult Congenital Heart Program. Children's National Hospital, George Washington University  
**Chair 2 Adriana Tremoulet:** UCSD

- Stanford Shulman: The history of Kawasaki Disease**
- Jane Newburger: "Treatment of Kawasaki disease: IVIG and beyond"**
- Brian McCrindle: Evidence Gaps in Guidelines**

LunchTime

**Acute Phase and New Therapy**  
**Chair 1** Hiroyuki Suzuki  
**Chair 2** Jane Newburger  
**Discussants 1** Tohru Kobayashi  
**Discussants 2** Kevin Friedman

- Masaru Miura :** Japanese new guidelines for treatment of Acute phase
- Koichi Miyata:** Prospective Observational Study on Efficacy of Acute Phase CST in a multicenter cohort of KD PEACOCK
- MingTai Lin:** : Evaluating the Efficacy of IVIg +Steroid for Prevention of CAA in Taiwanese with Refractory KD (RAST Study): a Trial
- Sagiv Eyal :** Etanercept with IVIg for Acute KD: A Long Term Follow Up on the EATAK Trial
- Adri. Tremoulet** Anakinra treatment in acuteKD patients with CAA: A Phase I/IIa trial
- Mitsuru Seki:** Prediction of response to continuous cyclosporine A infusion in patients with intravenous immunoglobulin-resistant Kawasaki disease
- Grainne M Murray:** Are high-risk scoring systems for Kawasaki disease applicable to patients in the UK?

**Yuki Lynn Takahashi Memorial Lecture**  
**Chair Masaru Miura**  
**Speaker Anne Rowley** "Cloning the Plasmablast Response to Identify the Cause of Kawasaki Disease".

**Late Breaking Session (All speakers are designated)**  
**Chair 1** Kei Takahashi  
**Chair 2** Michael Portman  
**Discussant 1** Kenji Furuno  
**Discussant 2** Kenichiro Yamamura

**3 speakers (20 minutes for each)**

- J. C Burns :** KIDCARE trial
- Moshe Arditi:** Progress and Update in Kawasaki disease pathophysiology and insights from mouse models
- Toshiro Hara:** Kawasaki Disease: its pathogenesis and pathophysiology revisited

**KD and MIS-C: Worldwide Epidemiology**  
**Chair 1** Hiroyuki Yamagishi  
**Chair 2** Min-Seob Song  
**Discussant 1** Eisuke Suganuma  
**Discussant 2** Nagib Dahdah

- Brian McCrindle:** KD in the time of COVID-19 – The evolution of the International KD Registry
- Roland Ulloa-Gutierrez:** Epidemiology of MIS-C in Latin American Children and Adolescents (MIS-C) associated with COVID-19
- Adrian Mendez-Aguilar:** MIS-C associated with SARS-CoV-2 and its relation to the severe forms of KD. Study from a single pediatric 3rd level facility from Mexico City
- Takuya Hara:** The impact of the COVID-19 State of Emergency on the incidence of Kawasaki disease or infectious disease in Japan
- Xie Liping:** KD is not Linked to COVID-19 in Chinese Pediatric Population
- Elisa Fernández-Cooke:** Prevalence and clinical characteristics of SARS-COV-2 confirmed and negative KD patients during the pandemic in Spain

**Parents Meeting : Tribute to Mr. Mitsuru Asai / Our Hopeful Future**  
**Chair 1** Yukako Yoshikane  
**Chair 2** Chisato Shimizu

- Keiko Ogasawara:** Tribute to Mr. Mitsuru Asai: from Japanese Association of the Children and Parents with Kawasaki Disease/The Movie Memories of Mr. M.Asai
- Akihiko Iwakiri(Japan):** The way to be with Kawasaki Disease
- Vanessa Gutierrez (USA) :** A brief introduction
- Matt Nelson/Ellen Xu (USA):** Update on KDF, and recognize Greg Chin's work over the past 20 years /The KDF youth group
- Australia: Rebecca Wilby and Nidal Raslan :** (Nidal will only be doing the last little bit of the PowerPoint):
  - KD Foundation Australia – our mission– our committee
  - Our KD community ▪ Highlights and achievements since the 12th IKDS ▪ Future plans ▪ KD Hero story
- Canada: Elizabeth Heald** (Board Chair, Kawasaki Disease Canada):

Free discussion

**Richard Rowe Memorial Session**  
**Chair Anne Rowley**  
**Speaker Kei Takahashi**

**MIS-C and KD: Clinical Achievements**  
**Chair 1** Shuichi Ito / **Chair 2** J.C. Burns  
**Discussant 1** Jackie Szmuszkovicz  
**Discussant 2** Yumi Mizuno

- Kaneta Kelli:** Distinguishing Features Between KD and SARS-CoV-2-Associated MIS-C 4,67 Children's Hospital Los Angeles, Los Angeles
- Jerin Jose:** COVID-19 Positive versus Negative Complete Kawasaki Disease
- Cedric Menlhoit :**Phenotypic topology and classification of pediatric patients investigated for KD and SARS-CoV-2 related illnesses during the COVID-19 pandemic
- Kyla Marie Cordrey:** The changing profile and management of patients diagnosed with KD before and during the SARS-CoV-2 pandemic
- Daisuke Matsubara:** Longitudinal Assessment of Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children Associated with COVID-19 Infections
- Adriana Trmoulet:** The progress of the treatment of MIS-C

**KD; New Approaches in Etiology**  
**Chair 1** Hiroyuki Matsuura  
**Chair 2** Hiromichi Hamada

Discussant 1 **Kazuyuki Ikeda**  
 Discussant 2 TBA

6 speakers

- Mofors Joanna:** Infections predisposing Kawasaki disease – a population-based study using the Swedish health-care registers
- Menikou Stephanie:** Seeking microbial origins of KD through metagenomics of the oropharynx
- Rocio Gutierrez Rojas:**Incidence of ethnic origins in province of Quebec and related risk of developing Kawasaki Disease
- Handoko Ryan:** Modulation of the severity of KD through concomitant environmental exposures
- Wei-Ting Wang:** Inflammasome Activation in KD and MIS-C
- Yoshiro Nagao:** Geographical Distribution of Force of Infection were similar between KD and paediatric viral infectious diseases in Japan

13	0	<b>Sponsored Seminar 1 (Mitsubishi Tanabe Pharma Corporation)</b> <b>Chair: Shuji Takei</b> <b>Speaker: Masaaki Mori</b> Positioning and usefulness of infliximab at the acute phase of Kawasaki disease	Lunch Time	Lunch Time
	10			
	20			
	30			
	40			
	50	<b>Special Lecture</b> <b>Chair: Yoshikazu Nakamura</b> <b>Speaker: Yoshihide Shibata:</b> Application of data analysis and numerical modeling technics in engineering to the medical data analysis	<b>Sponsored Seminar 3 (NIHON PHARMACEUTICAL CO.LTD)</b> <b>Chair: Tomoyo Matsubara</b> <b>Speaker: Akihiko Saitoh</b> Infections and Kawasaki Disease: Related or Unrelated?	<b>Sponsored Seminar 4 (Japan Blood Products Organization)</b> <b>Chair: Tohru Kobayashi</b> <b>Speaker 1: Shigeto Fuse</b> Glycerin enema as a pre-treatment in the patient with Kawasaki disease.  <b>Speaker 2: Kenji Furuno</b> Treatment of Kawasaki disease in the COVID-19 epidemic. - Do we need to be aware of the difference between 5% and 10% solutions?
14	0			
	10			
	20			
	30	<b>Diagnosis / Clinical Examinations</b>  <b>Chair 1 Tohru Kobayashi</b> <b>Chair 2 MingTai Lin</b> <b>Discussants 1 Yuichi Nomura</b> <b>Discussants 2 TBA</b>	<b>JSKD-APSC joint session ' Prospect of Asian Guidelines for CV complications of Kawasaki Disease'</b> <b>Chair 1 Yoshihide Mitani</b> <b>Chair 2 MeiHwan-Wu</b> <b>Discussants 1 Hiroyoshi Yokoi</b> Department of Health Science, International University of Health and Welfare, Fukuoka <b>Discussants 2 Lucy Youngmin Eun</b> Division of Pediatric Cardiology, Department of Pediatrics, Yonsei University College of Medicine, 5 speakers:( <b>All speakers are designated</b> )	<b>Cardiovascular Complications</b>  <b>Chair 1 Kenji Suda</b> <b>Chair 2 John Gordon</b> <b>Discussant 1 Kentaro Aso</b> <b>Discussant 2 Fujito Numano</b>
	40			
	50	<b>6 speakers</b> <b>1 (designated) Ayusawa Mamoru</b> he 6th Revision of Japanese Diagnostic Criteria <b>2 (designated) Ming Tai Lin</b> Techniques and Pitfalls in Coronary Echocardiography in KD patient	<b>1 Ryuji Fukazawa</b> (15min) Department of Pediatrics, Nippon Medical School, Tokyo, Japan <b>2 Ming-Tai LIN</b> (15min) Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan.	<b>1.Etsuko Tsuda</b> : Characteristics of coronary flow velocity reserve on transthoracic Doppler echocardiography in patients with a history of KD <b>2. Jennifer Ji Lee</b> The Hospital for Sick Children: The Long-term Cardiac and Non-Cardiac Prognosis of KD - A Systematic Review <b>3. Taichi Kato</b> Nagoya University Graduate School of Medicine: Analysis of the long-term clinical course and the factors associated with coronary arterial aneurysm regression in Kawasaki disease patients <b>4. Jane C. Burns</b> University of California San Diego Coronary artery remodeling after Kawasaki disease <b>5. Manphool Singhal</b> Comparison of Coronary Artery Dimensions on CT Coronary Angiography with 2D Echocardiography in Children with Kawasaki Disease: A Study from Chandigarh, North India <b>6. Hiroyuki Ohashi</b> : Potential Substrates for Acute Coronary Syndrome in Adults Long after Kawasaki Disease with Severe Coronary Artery Involvement: In Vivo Unprecedented Optical Coherence Tomography Based Phenotyping of Coronary Sequelae
15	0	<b>3 Yukako Yoshikane</b> Biomarkers of Tenascin C and Pentraxin 3 Predict the Treatment-Resistant Kawasaki Disease <b>4 Micheal Portman</b> Artificial Intelligence Derived Proteomic Panel to Diagnose Kawasaki Disease <b>5. Nicholas Dreger</b> Impact of Coronary Artery Z-score Models on the Classification of Coronary Involvement and Management of Kawasaki Disease <b>6 Larios Guillermo</b> Coronary arteries Z-Scores in Kawasaki disease. Are the different nomograms comparable?	<b>3 Yoshihide Mitani</b> (15min) Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie, Japan <b>4 Sidney Lo</b> (15min) Department of Cardiology, Liverpool Hospital and South Western Sydney Clinical School, The University of New South Wales, Sydney, NSW, Australia <b>5 Dr Khung Keong (KK) Yeo</b> (15min) Department of Cardiology, National Heart Center Singapore, Singapore	
	10			
	20			
	30			
	40			
	50			
16	0	<b>Pathogenesis and Genetics</b>  <b>Chair 1 Yoshihiro Onouchi</b> <b>Chair 2 Surjit Singh</b>  <b>Discussant Jun Abe</b> : Natioal Center of Child Health and Development  <b>1. Keynote: Yoshihiro Onouchi;</b> Newer development of genetic study of KD <b>2. Xue Fan</b> Expression profile analysis of Differentially Expressed Genes in Human Coronary Artery Endothelial Cells Induced by Serum from KD: A preliminary study <b>3. Heather Jackson</b> KD Patient Stratification and Pathway Analysis Based on Host Transcriptomic and Proteomic Profiles <b>4. Sadeep Shrestha</b> Whole-Genome Sequencing Analysis of IVIG response among KD patients <b>5. Ryusuke Ae</b> KD and pediatric infectious diseases during the coronavirus disease 2019 pandemic <b>6. Vishnuvardhan Reddy Konda</b> Nail-fold capillaroscopy changes in a single center cohort of patients with KD from North-West India	<b>Animal model / immunology/Novel experiment (Basic research)</b>  <b>Chair 1 Roland Cimaz</b> <b>Chair 2 Masaaki Mori</b>  <b>Discussant 1 Toshiaki Oharaseki</b> <b>Discussant 2 Masaki Shimizu</b>  7 speakers <b>1. Teramoto Yoshiki:</b> Gut microbiota as a susceptibility factor for Kawasaki disease <b>2. Marek Iannucci Stefanie</b> : Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of KD vasculitis by modulating the NLRP3 inflammasome. <b>3. Ben Croker</b> : Intravenous immunoglobulin is associated with the elimination of IL-1 $\beta$ expressing neutrophils in patients with KD and MIS-C (change ?) <b>4. Chisato Shimizu:</b> Endothelial cell response to atovaatatin <b>5. Rebecca Poritt:</b> Single-cell and spatial transcriptomics reveal NLRP3 inflammasome-mediated immune-stromal interactions during vasculitis and cardiovascular inflammation <b>6. Akio Matsuda:</b> Screening for novel drug candidates for treatment of IVIG-resistant Kawasaki disease	<b>Long term management and Transition</b> <b>Chair 1 Etsuko Tsuda</b> <b>Chair 2 Ryuji Fukazawa</b> <b>Discussant 1 Masahiro Kamada</b> <b>Discussant 2 Motofumi Iemura</b> <b>1. Tsuchihashi Tomoya</b> : Intimal thickening and disruption of the media occur in the arterial walls of CA not associated with CAL in patients with KD <b>2. Krsten Dummer:</b> The Use of Direct Oral Anticoagulants in Patients with Giant Coronary Atery Aneurysms related to KD <b>3. Eisuke Suganuma:</b> The effect of ARB/ACEi for regression of coronary aneurysm in KD patients: a subgroup analysis of the KIDCAR study (EARNEST) <b>4. Kathrine Hansen:</b> Physicians' self-reported exercise testing and physical activity recommendations in Kawasaki patients <b>5. Kato Masataka:</b> 'Clinical Significance of Perivascular Adipose Tissue Heterogeneity in KD with CAL <b>6. Kanae Tsuno</b> : Evaluation of the coronary circulation by <sup>13</sup> N-ammonia PET in the coronary artery lesion after KD
	10			
	20			
17	0			
	10			
	20			

30

**Sponsored Seminar 2 (Teijin Pharma Limited)**

**Chair: Mamoru Ayusawa**

**Speaker: Hiromichi Hamada**

40

Cooperation of Kawasaki disease medical care in Asia and its future perspective

50

18

0

10

**Moderated Poster (1)**

**Chair 1 : Masahiro Ishii**

**Chair 2 : Taco Kuijpers**

**1) Nita Chahal:** The psychosocial reality for adolescents and parents living with KD complicated by coronary artery aneurysms

**2) Marianna Fabi:** Gut microbiota dysbiosis in KD a perspective<br>comparative study

**3) John Kanegaye:** Dipstick and automated microscopic urinalysis (UA) to differentiate KD from UTI, the MIS-C, and other causes of fever

**4) KUO HO-CHANG:** Intravenous Immunoglobulin Treatment in KD Decreases the Incidence of Myopia

**5) Bregel Lyudmila:** Macrophage activation syndrome in Kawasaki Disease <br/>and MIS-C with COVID-19

**6) Cole Lyndsey:** Fulfillment of KD criteria and associated outcomes in MIS-C

**Moderated Poster (2)**

**Chair 1 : Tomoyo Matsubara**

**Chair 2 : Bregel Lyudmila**

**1) Jong-Woon Choi:** Epidemiology and Clinical Outcomes of Refractory Kawasaki Disease in Korea

**2) Toshimasa Nakada:** Acute Phase Treatment and Medium-Term Outcomes in Kawasaki Disease

**3) Chen Chu:** The safety of statin in early and middle stage after medication in children with Kawasaki disease complicated with coronary aneurysms

**4) Himanshi Chaudhary:** Pan Coronary Artery Involvement\* in Kawasaki Disease: a unique and hitherto unreported finding on Computed Tomography Coronary Angiography

**5) Michael Fridman:** The Utility of Cardiac Biomarkers in the Differentiation and Prognostication of KD versus MIS-C Associated with COVID-19

**6) Paul Tsoukas:** Proton pump inhibitors suppress IL-1 mediated carditis in a murine model of KD